Continuous Manufacturing On Horizon As Competitive Edge In OTC Space
This article was originally published in The Tan Sheet
Executive Summary
While OTC firms’ slimmer profit margins make equipment changes or other capital investments more difficult for them than for Rx firms, continuous manufacturing will be worth the investment, says CDER Director Janet Woodcock. “We’re going to see a lot of these out there,” she says.
You may also be interested in...
FDA Combines Supplement GMP Recordkeeping, Testing Waiver Estimates
On CRN Challenge, Nexus Formulas Gets Lesson On Supporting Ad Claims For Supplements
So full of errors were the firm's online ads for its Plavinol supplement, the National Advertising Division noted support for some claims contained "many of the same flaws" as others. The prevalence of problems prompted NAD to go outside its "scope of review" and note unclear instructions on Plavinol labels.
Perrigo Returns To 'Model' For Success, Expects Surprises From 2020 Launches
Perrigo "walked away a little bit" from "a model that worked beautifully," says CEO Murray Kessler at investor conference, "In essence, all we've done over the last year is to put back in place the model that worked so well."
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: